RHHBY
Roche Holding AG
Is RHHBY Halal?
Swiss pharmaceutical and diagnostics — permissible.
What You Should Know
Roche's 2025 Finance Report reports CHF 100,703 million of assets, CHF 31,636 million of debt, CHF 5,582 million of cash, CHF 9,894 million of marketable securities, CHF 11,506 million of receivables and CHF 63,356 million of revenue. Debt/assets is 31.42%, liquidity/assets is 15.37% and receivables-plus-cash/assets is 16.97%; the filing-based ratios pass, but group activity and a consolidated interest-income numerator remain incomplete.
⚠️ Concerns
- •Minor interest income
- •Pharmaceutical and diagnostics licensing mix
- •Marketable debt securities
- •Product-level prohibited revenue is not separately disclosed
Current quantitative Sharia screen
Based on Finance Report figures for the period ended 2025-12-31; calculated 2026-07-15.
31,636 / 100,703
15,476 / 100,703
17,088 / 100,703
- Financial
- Incomplete
- Overall
- Incomplete
Debt/assets is 31.42%, liquidity/assets is 15.37%, and receivables-plus-cash/assets is 16.97%; gross interest income is unavailable and activity remains incomplete.
- Financial
- Pass
- Overall
- Incomplete
Debt/assets, liquidity/assets and receivables-plus-cash/assets are below the examined MSCI limits; activity remains incomplete.
- Financial
- Pass
- Overall
- Incomplete
Debt/assets is 31.42% and liquidity/assets is 15.37%; the activity calculation is incomplete and this is not an official SAC classification.
- Financial
- Not calculated
- Overall
- Incomplete
A licensed historical market-cap series is not stored; filing-based ratios pass but activity and purification remain incomplete.
Business-activity disclosure
Roche develops medicines and diagnostic solutions, generally permissible healthcare activities.
Limitation: The group reports a broad pharmaceutical and diagnostics portfolio but does not reduce every product, licensing and customer stream to a universal prohibited-revenue numerator.
Purification
The group report does not isolate a complete prohibited-revenue or interest-income numerator, so no scholar-approved purification percentage is inferred.
Inputs, assumptions and primary sources
- Amounts are CHF millions from Roche's 2025 consolidated balance sheet and income statement.
- Long-term debt is CHF 27,430 million and short-term debt is CHF 4,206 million; lease liabilities are not added because the consolidated balance sheet presents debt separately.
- Cash is CHF 5,582 million, marketable securities are CHF 9,894 million, and accounts receivable are CHF 11,506 million.
- Group revenue is CHF 63,356 million (sales of CHF 61,516 million plus other revenue of CHF 1,840 million). A group-level interest-income numerator is not isolated in the consolidated statement.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →